The prospect of drugs for rare diseases is promising, a pharmaceutical enterprise invests 20 million US dollars into the Bureau
Time of Update: 2020-02-19
For example, in terms of policy, in January last year, the state decided to give value-added tax preference to rare disease treatment drugs.
In 2020, the development of the pharmaceutical industry will present three major trends
Time of Update: 2020-02-10
[pharmaceutical network industry trends] looking back on the past year, for pharmaceutical enterprises, some have unlimited development prospects, others are expected to shrink in the market or the company's profits do not meet expectations.
Zhongsheng Pharmaceutical Co., Ltd.: RuiChuang liver disease innovative medicine, a subsidiary, obtained the US patent certificate
Time of Update: 2020-01-19
Zsp0678 is an innovative drug for the treatment of nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), which has a clear mechanism of action and independent intellectual property rights.
In the next 10 years, China's three major focuses in the field of biomedicine deserve attention
Time of Update: 2019-12-28
In 2018, the revenue of several top listed companies in biomedical related fields, such as McAb, blood products, vaccines and so on, exceeded 100 million yuan, achieving year-on-year growth and good industry development trend.
Zhongsheng group's products are patented in Europe and plan to cover the world
Time of Update: 2019-10-15
On October 14, Guangdong Zhongsheng Pharmaceutical Co., Ltd
(hereinafter referred to as "Zhongsheng") released the announcement on obtaining the European patent
Yaozhitong cro platform that can be seen by 100 + organizations in one second
Time of Update: 2017-11-22
Yaozhitong cro platform enterprise display platform enterprise display currently includes: clinical, preclinical, new drug research and development, be.
Two heavyweight new drugs will be launched in Xiansheng pharmaceutical next year
Time of Update: 2015-12-02
Different from the habit of "building a car behind closed doors" of domestic enterprises, the pioneer pharmaceutical industry has chosen to open the door and welcome colleagues to explore new drug research and development together.
Future trend of biopharmaceutical cro in 2015
Time of Update: 2014-11-05
1、 In 2015, the cro market scale reached $70 billion in biomedical outsourcing, which means that pharmaceutical companies engage in their own core business and transfer the non